Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure
- 3 May 2001
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (18), 1358-1365
- https://doi.org/10.1056/nejm200105033441803
Abstract
The benefits of angiotensin-converting–enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure.Keywords
This publication has 31 references indexed in Scilit:
- Racial differences in patients with heart failureClinical Cardiology, 1999
- Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trialsJournal of Cardiac Failure, 1999
- Racial Differences in the Outcome of Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failureThe American Journal of Cardiology, 1998
- Hospitalization for congestive heart failure. Explaining racial differencesJAMA, 1995
- Racial differences in cardiac structure and function in essential hypertensionBMJ, 1994
- Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with PlaceboNew England Journal of Medicine, 1993
- Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalenceArchives of Internal Medicine, 1990
- Hypertension in minority populationsThe American Journal of Medicine, 1990
- A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in responseJAMA, 1986